SciCann Therapeutics

Cannabis and Cannabinoid Pharmaceuticals

Health Tech & Life Sciences
Non Active, Jul 2022 ceased to operate

Company Overview

Snapshot

Founded in June 2017 by Zohar Koren and Sheldon Inentash, SciCann Therapeutics operated with 1–10 employees. The company raised $3 million across one funding round from FSD Pharma. In October 2019, SciCann Therapeutics received a notice of allowance for its enhanced CBD therapy US patent for NASH.

Business overview

SciCann Therapeutics was a Canadian-Israeli pharmaceutical company focused on developing and commercializing pharmaceutical products that target and modulate the endocannabinoid system. The company's core technology involved new therapeutic agents, drug candidates, novel cannabis genetics, and personalized treatment tools. SciCann Therapeutics operated in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Medical Cannabis, serving markets in oncology, pain management, neurodegenerative diseases, and inflammatory disorders.

Strategic signal

In October 2019, SciCann Therapeutics received a notice of allowance for its US patent related to enhanced CBD therapy for NASH. This milestone indicated progress in the company's intellectual property development and its focus on specific therapeutic applications within the cannabinoid pharmaceutical space, signaling potential for future product development and market differentiation.

Company Intelligence Q&A

What was the operational status of SciCann Therapeutics?
SciCann Therapeutics ceased to operate in July 2022, and its status is Non Active.
When was SciCann Therapeutics founded and by whom?
SciCann Therapeutics was founded in June 2017 by Zohar Koren and Sheldon Inentash.
What was a key intellectual property milestone for SciCann Therapeutics?
In October 2019, SciCann Therapeutics received a notice of allowance for its US patent for enhanced CBD therapy targeting NASH.
What was the total capital raised by SciCann Therapeutics?
SciCann Therapeutics raised a total of $3 million across one funding round.
Did SciCann Therapeutics engage in research collaborations?
In September 2018, FSD Pharma and SciCann Therapeutics launched a cardiovascular research program in Tel Aviv University. In February 2019, SciCann Therapeutics launched a liver disease research program, also in Tel Aviv University.